Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study Assessing the Safety and Performance of SGM-101, a Fluorochrome-labeled Anti-carcino-embryonic Antigen Monoclonal Antibody for the Detection of Neoplastic Lesions in Patients With Colorectal Cancer or Pancreatic Cancer

Next Previous
X
Search
Trial Profile

A Phase I Study Assessing the Safety and Performance of SGM-101, a Fluorochrome-labeled Anti-carcino-embryonic Antigen Monoclonal Antibody for the Detection of Neoplastic Lesions in Patients With Colorectal Cancer or Pancreatic Cancer

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 03 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SGM 101 (Primary)
  • Indications Adenocarcinoma; Carcinoma; Colon cancer; Colorectal cancer; Fibrosis; Intestinal cancer; Pancreatic cancer; Rectal cancer
  • Focus Adverse reactions
  • Sponsors SurgiMAb

    • Most Recent Events

    • 16 Jul 2019 Status changed from recruiting to completed.
    • 16 Jul 2019 Results presented in a SurgiMAb media release.
    • 16 Jul 2019 According to a SurgiMAb media release, results (n=75) were published in The Lancet Gastroenterology & Hepatology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top